Typbar-TCV

The World Health Organization (WHO) announced the prequalification of the first conjugate vaccine for typhoid for children over 6 months of age in endemic countries. The existing typhoid vaccines are not approved for children younger than 2 years of age.

• Immunization with the typhoid conjugate vaccine (TCV) or Typbar-TCV is safe, well tolerated and will have a significant impact on disease incidence in endemic areas that introduce it.
• Prequalified by WHO means that the Typbar-TCV vaccine met quality, safety and efficacy standards, and is eligible for procurement by various UN agencies. Prequalification is a crucial next step to enable vaccines to become available in low-income countries, where the need is the greatest.
• Typhoid conjugate vaccines (TCVs) are innovative products that have longer-lasting immunity than older vaccines, require fewer doses, and can be given to young children through routine childhood immunization programs, says the WHO.